

**FORM 3**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

<b>1. Name and Address of Reporting Person</b> <u>Pauwels Eric</u>  (Last) (First) (Middle) C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT  (Street) SOUTH PLAINFIELD NJ 07080  (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> 04/16/2020	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>PTC THERAPEUTICS, INC. [ PTCT ]</u>	
		<b>4. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Business Officer	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	23,841 <sup>(1)</sup>	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)						
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (Right To Buy)	(2)	04/07/2025	Common Stock	70,000	66.15	D
Stock Option (Right To Buy)	(2)	01/03/2026	Common Stock	20,411	30.86	D
Stock Option (Right To Buy)	(2)	02/24/2026	Common Stock	2,488	11.32	D
Stock Option (Right To Buy)	(3)	01/02/2027	Common Stock	8,423	11.23	D
Stock Option (Right To Buy)	(4)	01/02/2028	Common Stock	30,594	18.01	D
Stock Option (Right To Buy)	(5)	01/21/2029	Common Stock	26,950	33.02	D
Stock Option (Right To Buy)	(6)	01/28/2030	Common Stock	28,210	51.16	D

**Explanation of Responses:**

- Includes: 1) 825 unvested shares of restricted stock from a January 3, 2017 grant of 3,300 shares of restricted stock, which vests in four equal annual installments over four years, commencing on January 3, 2018; 2) 4,600 unvested shares of restricted stock from a January 3, 2018 grant of 9,200 shares of restricted stock, which vests in four equal annual installments over four years, commencing on January 3, 2019; 3) 3,465 unvested shares of restricted stock from a January 22, 2019 grant of 4,620 shares of restricted stock, which vests over four years, commencing on January 22, 2020; and 4) 4,790 unvested Restricted Stock Units ("RSUs") from an award of 4,790 RSUs granted on January 29, 2020, which vests in four equal annual installments over four years, commencing on January 29, 2021.
- Currently exercisable.
- This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
- This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
- This option was granted on January 22, 2019, and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 22, 2020.
- This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.

**Remarks:**

/s/ Avraham S. Adler, attorney-in-fact      04/17/2020  
 \*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Donald Mankoff, Mark Boulding, Avraham Adler as  
(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of PTC Therapeutics, Inc. (the "C  
(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute :  
(3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's s  
(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in fact, may be of be  
The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever :  
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 15th day of April, 2020.

/s/Eric Pauwels  
Signature

Eric Pauwels  
Print Name